These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1733433)

  • 1. Breast cancer and specific types of combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Thomas DB; Noonan EA
    Br J Cancer; 1992 Jan; 65(1):108-13. PubMed ID: 1733433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer.
    Contraception; 1996 Sep; 54(3 Suppl):1S-106S. PubMed ID: 8899264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exogenous progestins and breast cancer.
    Stanford JL; Thomas DB
    Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Rosenblatt KA; Thomas DB
    Int J Cancer; 1991 Dec; 49(6):870-4. PubMed ID: 1959990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormonal contraception].
    Van Cauwenberge JR
    Rev Med Liege; 1992 May; 47(5):221-36. PubMed ID: 1604074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.
    Iversen L; Fielding S; Lidegaard Ø; Mørch LS; Skovlund CW; Hannaford PC
    BMJ; 2018 Sep; 362():k3609. PubMed ID: 30257920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestins and breast cancer: an epidemiologic review.
    Staffa JA; Newschaffer CJ; Jones JK; Miller V
    Fertil Steril; 1992 Mar; 57(3):473-91. PubMed ID: 1740192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations.
    Bernstein L
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):288-96. PubMed ID: 16611204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Lancet; 1997 Apr; 349(9060):1202-9. PubMed ID: 9130941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer and combined oral contraceptives: results from a multinational study. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Br J Cancer; 1990 Jan; 61(1):110-9. PubMed ID: 2404507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer.
    Strom BL; Berlin JA; Weber AL; Norman SA; Bernstein L; Burkman RT; Daling JR; Deapen D; Folger SG; Malone KE; Marchbanks PA; Simon MS; Ursin G; Weiss LK; Spirtas R
    Contraception; 2004 May; 69(5):353-60. PubMed ID: 15105056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptives in the United States: trends in content and potency.
    Piper JM; Kennedy DL
    Int J Epidemiol; 1987 Jun; 16(2):215-21. PubMed ID: 3301706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Rosenblatt KA; Thomas DB; Noonan EA
    Eur J Cancer; 1992; 28A(11):1872-6. PubMed ID: 1389530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives.
    Thomas DB; Ray RM
    Am J Epidemiol; 1996 Aug; 144(3):281-9. PubMed ID: 8686697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
    Maxwell GL; Schildkraut JM; Calingaert B; Risinger JI; Dainty L; Marchbanks PA; Berchuck A; Barrett JC; Rodriguez GC
    Gynecol Oncol; 2006 Nov; 103(2):535-40. PubMed ID: 16740300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.